Eisai traded at 5,399.00 this Wednesday May 25th, decreasing 43.00 or 0.79 percent since the previous trading session. Looking back, over the last four weeks, Eisai lost 3.52 percent. Over the last 12 months, its price fell by 22.90 percent. Looking ahead, we forecast Eisai to be priced at 5,300.42 by the end of this quarter and at 4,788.34 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
5,399.00
Daily Change
-0.79%
Yearly
-22.90%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
M3 Inc 3,813.00 -47.00 -1.22% -47.70%
Kyowa Hakko Kirin 2,740.00 6.00 0.22% -18.45%
Takeda 3,780.00 -17.00 -0.45% 0.99%
Astellas Pharma 2,006.00 17.00 0.85% 20.73%
Sumitomo Dainippon 1,072.00 -10.00 -0.92% -49.62%
Shionogi 6,887.00 -7.00 -0.10% 21.66%
Chugai Pharma 3,537.00 -14.00 -0.39% -14.32%
Eisai 5,399.00 -43.00 -0.79% -22.90%
Terumo 4,151.00 27.00 0.65% -0.72%
Daiichi Sankyo 3,389.00 19.00 0.56% 32.02%
Otsuka Holdings 4,460.00 -7.00 -0.16% -0.22%

Indexes Price Day Year
JP225 26678 -70.34 -0.26% -6.86%

Eisai
Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Oceania), Asia and Latin America (South Korea, Taiwan, Hong Kong, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.